Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
PRGN-3005
i
Other names:
PRGN-3005, PRGN-3005 UltraCAR-T, PRGN3005, PRGN 3005
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Precigen
Drug class:
IL-15-targeted CAR-T immunotherapy, MUC16-targeted CAR-T immunotherapy
Related drugs:
‹
GPC3-CAR and IL15 plus IL21 (0)
JCAR020 (0)
GPC3-CAR and IL15 plus IL21 (0)
JCAR020 (0)
›
Associations
News
Trials
Phase
Status
Apply
Phase
Status
Apply
Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer (NCT03907527)
Phase 1
Precigen, Inc
Precigen, Inc
Recruiting
Phase 1
Precigen, Inc
Recruiting
Last update posted :
11/13/2023
Initiation :
04/30/2019
Primary completion :
12/15/2024
Completion :
11/15/2028
BRCA
|
BRCA mutation
|
PRGN-3005
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login